T. Rowe Price Associates, Inc. 13D and 13G filings for Blueprint Medicines Corporation:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 1:07 pm Sale | 2025-06-30 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 1,465,036 2.300% | -3,922,231 (-72.81%) | Filing |
| 2024-11-14 1:22 pm Sale | 2024-09-30 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 5,387,267 8.500% | -863,556 (-13.82%) | Filing |
| 2024-04-10 12:58 pm Purchase | 2024-03-31 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 6,250,823 10.200% | 815,206 (+15.00%) | Filing |
| 2024-02-14 10:03 am Purchase | 2023-12-31 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 5,435,617 8.900% | 1,136,327 (+26.43%) | Filing |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 4,299,290 7.200% | -251,249 (-5.52%) | Filing |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 4,550,539 7.700% | 862,773 (+23.40%) | Filing |
| 2021-02-16 12:23 pm Purchase | 2020-12-31 | 13G | Blueprint Medicines Corporation BPMC | T. Rowe Price Associates, Inc. | 3,687,766 6.600% | 334,199 (+9.97%) | Filing |